A lower-dose, less-toxic regimen of oxaliplatin and capecitabine conferred comparable PFS as the higher-dose regimen among frail and/or elderly patients with advanced gastroesophageal cancer, according to results from the randomized phase 3 GO2 trial scheduled for presentation at ASCO Annual Meeting.
Lower-dose chemotherapy benefits older, frail patients with advanced gastroesophageal cancer